← All indications
Lymphoma, Follicular
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
Drugs by status
Approved for this indication (14)
Phase 4 trials (9)
Phase 3 trials (37)
- cd19 car-t cells
- tocilizumab
- hyaluronidase (human recombinant)
- autologous mononuclear stem cell
- epirubicin
- sirolimus
- ofatumumab
- allogeneic bone marrow
- autologous umbilical cord blood
- ibrutinib
- cpi-818
- aldesleukin
- Epcoritamab
- gemcitabine
- regn1979
- etoposide
- ublituximab
- pralatrexate
- pixuvri
- tafasitamab
- autologous hematopoietic stem cells
- tqb2825
- urea
- parsaclisib
- carmustine
- mitoxantrone
- fludarabine
- inotuzumab ozogamicin
- TNB-486
- cerdulatinib
- +7 more
Phase 2 trials (163)
- bryostatin
- e7777
- pneumococcal 13-valent conjugate vaccine
- thalidomide
- carboplatin
- Anti-thymocyte Globulin (Rabbit)
- dexamethasone
- avadomide
- autologous cd19/cd22 chimeric antigen receptor t-cells
- lentivirus vector ccr5 shrna/trim5alpha/tar decoy-transduced autologous cd34-positive hematopoietic progenitor cells
- naltrexone
- cyclosporine
- stro-001
- dtrm-555
- plerixafor
- n-(4-hydroxyphenyl)all-trans retinamide
- melphalan
- fludeoxyglucose f-18
- enzastaurin
- vnx-101
- hsc835
- bortezomib
- tacrolimus
- cd3+ teff cells
- autologous effector lymphocytes expanded ex-vivo
- allogeneic hematopoietic stem cells
- alvocidib
- agatolimod
- cytarabine
- aldoxorubicin
- +133 more
Phase 1 trials (125)
- lucatumumab
- clbr001
- bms-986178
- buparlisib
- personalized synthetic long peptide vaccine
- ly4152199
- utomilumab
- morab-004
- rifampin
- qs-21
- id-klh vaccine
- cd22 car-t cells
- cd20-tcb
- inactivated influenza vaccine
- immu-114
- PSB107
- sgr-1505
- tg-1801
- magrolimab
- 64cu-llp2a
- rpm cd19-mbil15-car-t cells
- in111 anti-cd45 monoclonal antibody bc8
- itraconazole
- bgb-21447
- nx-2127
- cefepime
- PSB102
- gm-csf k562 cells
- rd14-01 cell
- imatinib
- +95 more
Other trials (22)
- palifermin
- lithium
- foscarnet
- zr-dfo-rb6
- resca-rd06
- deferasirox
- dendritic cell tumor fusion vaccine
- arsenic trioxide
- phosphorothiolate oligodeoxyribonucleotide
- o6-benzylguanine
- triamcinolone
- follitropin alfa
- zr-dfo-r8b4
- bexarotene
- ga-nota-rd06
- [18f]rccb6
- zr-dfo-rd06
- chia seed
- valganciclovir
- ga-nota-r8b4
- ganciclovir
- resca-r8b4
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (69)
- Incyte
- Spectrum Pharmaceuticals
- Celgene
- Sandoz
- Pharmacyclics
- Genentech
- Pfizer
- Biogen
- Novartis
- Archigen Biotech Limited
- Biocad
- Biovest International
- CTI BioPharma
- Celltrion
- GlaxoSmithKline
- Parexel
- Shanghai Henlius Biotech
- Boehringer Ingelheim
- Epizyme, Inc.
- Center for International Blood and Marrow Transplant Research
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- University of Pennsylvania
- Azienda Ospedaliera San Giovanni Battista
- Cancer Research UK
- Centre Leon Berard
- University of London
- Eastern Cooperative Oncology Group
- German Low Grade Lymphoma Study Group
- +39 more
Organization Involved with Phase 2 Indications (119)
- Zhejiang DTRM Biopharma
- AbbVie
- Seattle Genetics
- Cephalon
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Immunomedics
- Merck
- Eli Lilly
- Plexxikon
- Genzyme
- Wyeth
- Asana BioSciences
- Ascenta Therapeutics
- BeOne Medicines
- Beijing Mabworks Biotech Co., Ltd.
- Centaurus Biopharma Co., Ltd.
- CureTech Ltd
- Immune Design
- Innovent Biologics (Suzhou) Co. Ltd.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Juno Therapeutics, Inc.
- MethylGene Inc.
- Mundipharma
- Sunesis Pharmaceuticals
- Xeme Biopharma Inc.
- Agenus Inc.
- PrECOG, LLC.
- TG Therapeutics, Inc.
- The Christie NHS Foundation Trust
- +89 more
Organization Involved with Phase 1 Indications (37)
- ADC Therapeutics SARL
- Amgen
- Morphotek
- AstraZeneca
- Arno Therapeutics
- ArQule
- Biointegrator LLC
- Thor Medical
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Sponsor GmbH
- SymBio Pharmaceuticals
- Triphase Research and Development Corporation
- Anhui Medical University
- Brown University
- California Institute for Biomedical Research
- Johns Hopkins University
- Rhode Island Hospital
- University of South Florida
- Wake Forest University
- Austin Health
- Fudan University
- Olivia Newton-John Cancer Research Institute
- University of California, San Diego
- University of Copenhagen
- The Parker Institute
- Icon Genetics
- University of Wisconsin
- Washington University in St. Louis
- ICON
- Damon Runyon Cancer Research Foundation
- +7 more
Organization Involved with Other Experimental Indications (5)